达格列净对瓣膜病心力衰竭患者临床疗效观察  

To Observe the Clinical Effect of Daglizin on Valvular Heart Failure Patients

作　　者：高俊杰 李润军[2] 张丽芳 汤秀英[1] Gao Junjie;Li Runjun;Zhang Lifang;Tang Xiuying(Qinhuangdao First Hospital Cardiovascular Department(Chest Pain Center)Qinhuangdao,066000.China;不详)

机构地区：[1]秦皇岛市第一医院心血管内科(胸痛中心),秦皇岛066000 [2]秦皇岛市第一医院重症医学科,秦皇岛066000

出　　处：《中国循证心血管医学杂志》2024年第11期1306-1308,1313,共4页Chinese Journal of Evidence-Based Cardiovascular Medicine

基　　金：河北省卫生健康委员会项目(20201314);秦皇岛市科学技术厅项目(202301A048)。

摘　　要：目的研究达格列净在瓣膜病心力衰竭患者中的治疗效果。方法选择2020年1月至2022年1月于秦皇岛市第一医院心脏内科治疗的97例瓣膜病心力衰竭患者作为研究对象。采用随机数表法将患者分为对照组(n=41)和观察组(n=56)。对照组给予血管紧张素转换酶抑制剂、利尿剂、β受体阻滞剂等常规治疗,观察组在对照组治疗的基础上加用达格列净(口服,10 mg,qd)治疗。治疗3月后,比较对照组与观察组患者心脏功能学指标,如左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD),以及心脏功能标志物N末端脑钠肽前体(NT-proBNP)、心脏炎性标志物超敏C反应蛋白(hs-CRP)以及心力衰竭生活质量量表(MLHFQ)评分情况。结果与治疗前相比,两组患者治疗后左室射血分数均升高,且观察组高于对照组,差异有统计学意义(P<0.05);与治疗前相比,两组患者治疗后LVESD和LVEDD均降低,且观察组低于对照组,差异有统计学意义(P<0.05)。与治疗前相比,两组患者治疗后NT-proBNP、hs-CRP水平以及心力衰竭生活质量量表(MLHFQ)评分均降低,且观察组低于对照组,差异有统计学意义(P<0.05),提示心脏功能标志物、心脏炎性标志物和生活质量改善。预后调查结果显示,观察组患者生存率高于对照组,且差异具有统计学意义(P<0.05)。结论达格列净在瓣膜病心力衰竭患者中疗效显著,积极应用达格列净可更好地帮助患者改善心脏相关指标,提高生活质量。Objective To study the therapeutic effect of daglizin in patients with valvular heart failure.Methods 97 patients with valvular heart failure who were treated in the Department of Cardiology of the First Hospital of Qinhuangdao City from January 2020 to January 2022 were selected as the study objects.The patients were divided into control group(n=41)and observation group(n=56)by random way.The control group was given routine primary treatment such as angiotensin-converting enzyme inhibitors,diuretics andβ-blockers.The observation group was additionally given dagaglizin(10 mg each time,once a day,orally administered)on the basis of the control group.After 3 months of treatment,compared the cardiac functional indexes such as left ventricular ejection fraction(LVEF)、left ventricular end-systolic diameter(LVESD)and left ventricular end-diastolic diameter(LVEDD),and the cardiac function marker N-terminal pro-B-type natriuretic peptide(NT-proBNP),cardiac inflammatory marker high-sensitivity C-reactive protein(hs-CRP)and the score of heart failure quality of Life questionnaire(MLHFQ)were recorded.Results Compared with before treatment,both groups of patients showed an increase in left ventricular ejection fraction after treatment,and the observation group was higher than the control group,with a statistically significant difference(P<0.05);compared with before treatment,both groups of patients showed a decrease in left ventricular end systolic diameter(LVESD)and left ventricular end diastolic diameter(LVEDD)after treatment,and the observation group was lower than the control group,with a statistically significant difference(P<0.05).Compared with before treatment,the levels of N-terminal B-type natriuretic peptide precursor(NT-proBNP),high-sensitivity C-reactive protein(hs-CRP),and heart failure quality of life questionnaire(MLHFQ)scores in both groups of patients decreased after treatment,and the observation group was lower than the control group,with statistical significance(P<0.05),tips for improving cardiac enzyme

关 键 词：心力衰竭 达格列净 瓣膜病 临床疗效 观察研究 

分 类 号：R541.6[医药卫生—心血管疾病]